TolterodineHydrobromide
CAS: 837376-36-0
Ref. 3D-FT148292
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar | ||
| 250mg | A consultar | ||
| 500mg | A consultar |
Informação sobre produto
- 2-[3-(Diisopropylamino)-1-phenylpropyl]-4-methylphenol hydrobromide
- 2-[3-[Bis(1-Methylethyl)Amino]-1-Phenylpropyl]-4-Methylphenol Hydrobromide
- 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol hydrobromide
- N,N-Diisopropyl-3-(2-hydroxy-5-Methylphenyl)-3-Phenylpropylamine HBr
- N,N-Diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine hydrobromide
- N,N-Diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine hydrobromide
- Phenol, 2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-, hydrobromide
- Phenol, 2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-, hydrobromide (1:1)
- Racemic tolterodine hydrobromide
Tolterodine is a prodrug that is converted to its active form, tolterodine tartrate, by sulfonation of the diisopropylamine moiety. Tolterodine has a high affinity for the ileal and vesical muscarinic receptors and is used in the treatment of overactive bladder and urinary incontinence. The conversion of tolterodine to its active form can be inhibited by markers such as erythromycin, ketoconazole, or itraconazole. Tolterodine also has enantiomeric forms (d-tolterodine and l-tolterodine). The presence of d-tolterodine was shown to be associated with increased efficacy in patients with overactive bladder symptoms who have been treated with this drug.
Propriedades químicas
Consulta técnica sobre: 3D-FT148292 TolterodineHydrobromide
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
